title: Clinical drug trials in Alzheimer disease. What are some of the issues?
abstract: Clinical drug trials in Alzheimer disease are underway in many locations throughout the world. That experience has uncovered a number of unique difficulties. In response, members of the Alzheimer's Association Medical and Scientific Advisory Board organized meetings with experts from the government, academia, private practice and the pharmaceutical industry. The issues are presented here along with some suggestions to facilitate planning and to avoid problems in future drug trials.
authors: Department of Psychiatry, University of California, Los Angeles.
authors: L F
authors: LF
authors: Jarvik
authors: L
authors: L
authors: Berg
authors: R
authors: R
authors: Bartus
authors: L
authors: L
authors: Heston
authors: N
authors: N
authors: Leith
authors: C
authors: C
authors: Phelps
authors: R
authors: R
authors: Shader
authors: P
authors: P
authors: Whitehouse
mesh_terms: D000367:Age Factors; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D002986:Clinical Trials as Topic / Q000592:standards*; D015897:Comorbidity; D004992:Ethics, Medical; D006801:Humans; D007258:Informed Consent; D010043:Outcome and Process Assessment, Health Care; D010919:Placebos; D016032:Randomized Controlled Trials as Topic / Q000592:standards; D012107:Research Design / Q000592:standards; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
chemical_list: D010919:Placebos